• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

重组 OC43 SARS-CoV-2 刺突替代病毒：一种用于 SARS-CoV-2 中和测定的改良 BSL-2 替代病毒。

Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays.

机构信息

Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.

出版信息

Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2310421121. doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8.

DOI:10.1073/pnas.2310421121
PMID:38976733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11260102/
Abstract

We generated a replication-competent OC43 human seasonal coronavirus (CoV) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike in place of the native spike (rOC43-CoV2 S). This virus is highly attenuated relative to OC43 and SARS-CoV-2 in cultured cells and animals and is classified as a biosafety level 2 (BSL-2) agent by the NIH biosafety committee. Neutralization of rOC43-CoV2 S and SARS-CoV-2 by S-specific monoclonal antibodies and human sera is highly correlated, unlike recombinant vesicular stomatitis virus-CoV2 S. Single-dose immunization with rOC43-CoV2 S generates high levels of neutralizing antibodies against SARS-CoV-2 and fully protects human ACE2 transgenic mice from SARS-CoV-2 lethal challenge, despite nondetectable replication in respiratory and nonrespiratory organs. rOC43-CoV2 S induces S-specific serum and airway mucosal immunoglobulin A and IgG responses in rhesus macaques. rOC43-CoV2 S has enormous value as a BSL-2 agent to measure S-specific antibodies in the context of a bona fide CoV and is a candidate live attenuated SARS-CoV-2 mucosal vaccine that preferentially replicates in the upper airway.

摘要

我们构建了一株能够复制的 OC43 季节性人类冠状病毒（CoV），其 Spike 蛋白被 SARS-CoV-2 的 Spike 蛋白取代（rOC43-CoV2 S）。与 OC43 和 SARS-CoV-2 相比，该病毒在细胞和动物中具有高度减毒特性，并且被 NIH 生物安全委员会归类为生物安全级别 2（BSL-2）试剂。rOC43-CoV2 S 和 SARS-CoV-2 的中和作用与 S 特异性单克隆抗体和人血清高度相关，与重组水疱性口炎病毒-CoV2 S 不同。单次免疫 rOC43-CoV2 S 可产生针对 SARS-CoV-2 的高水平中和抗体，并完全保护人 ACE2 转基因小鼠免受 SARS-CoV-2 的致命攻击，尽管在呼吸道和非呼吸道器官中无法检测到复制。rOC43-CoV2 S 可诱导恒河猴产生 S 特异性血清和气道黏膜免疫球蛋白 A 和 IgG 反应。rOC43-CoV2 S 作为 BSL-2 试剂具有巨大的价值，可在真正的 CoV 背景下测量 S 特异性抗体，并且是一种候选的活减毒 SARS-CoV-2 黏膜疫苗，优先在上呼吸道复制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/5b74a53c2a60/pnas.2310421121fig07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/ed86b7e0be6f/pnas.2310421121fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/00d2f0a4f6b1/pnas.2310421121fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/595bc7fdbe80/pnas.2310421121fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/725f1b90c21e/pnas.2310421121fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/eac681711dc3/pnas.2310421121fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/8e6cdff9a867/pnas.2310421121fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/5b74a53c2a60/pnas.2310421121fig07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/ed86b7e0be6f/pnas.2310421121fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/00d2f0a4f6b1/pnas.2310421121fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/595bc7fdbe80/pnas.2310421121fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/725f1b90c21e/pnas.2310421121fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/eac681711dc3/pnas.2310421121fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/8e6cdff9a867/pnas.2310421121fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83df/11260102/5b74a53c2a60/pnas.2310421121fig07.jpg

相似文献

1
Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays.重组 OC43 SARS-CoV-2 刺突替代病毒：一种用于 SARS-CoV-2 中和测定的改良 BSL-2 替代病毒。
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2310421121. doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8.
2
A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.一种表达融合前稳定的 SARS-CoV-2 刺突蛋白的 MVA 疫苗单次接种即可中和关注变体，并保护小鼠免受致死性 SARS-CoV-2 感染。
Front Immunol. 2022 Jan 27;12:824728. doi: 10.3389/fimmu.2021.824728. eCollection 2021.
3
A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.基于水疱性口炎病毒的疫苗接种策略诱导针对 SARS-CoV-2 的强大和保护性中和抗体。
PLoS Pathog. 2021 Dec 16;17(12):e1010092. doi: 10.1371/journal.ppat.1010092. eCollection 2021 Dec.
4
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.鉴定导致 SARS-CoV-2 刺突突变的单克隆和血清抗体中和作用减弱的抗体。
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4. doi: 10.1016/j.chom.2021.01.014. Epub 2021 Jan 27.
5
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
6
Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.在小鼠和非人类灵长类动物模型中，接种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗可提供针对普通感冒冠状病毒的低水平交叉保护。
J Virol. 2025 Feb 25;99(2):e0139024. doi: 10.1128/jvi.01390-24. Epub 2025 Jan 16.
7
Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters.鼻内给予HD-Ad-FS疫苗可在小鼠和仓鼠中诱导针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的全身和气道黏膜免疫以及针对SARS-CoV-2变体的全身免疫。
Front Immunol. 2024 Aug 30;15:1430928. doi: 10.3389/fimmu.2024.1430928. eCollection 2024.
8
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.针对人冠状病毒 OC43 刺突蛋白的交叉反应性抗体与 COVID-19 患者的疾病严重程度相关：一项回顾性研究。
Emerg Microbes Infect. 2021 Dec;10(1):664-676. doi: 10.1080/22221751.2021.1905488.
9
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.利用具有 SARS-CoV-2 刺突蛋白的水疱性口炎病毒评估 SARS-CoV-2 中和抗体。
Virol J. 2021 Jan 12;18(1):16. doi: 10.1186/s12985-021-01490-7.
10
Potently neutralizing and protective human antibodies against SARS-CoV-2.强效中和和保护 SARS-CoV-2 的人源抗体。
Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15.

引用本文的文献

1
Assembly and Mutagenesis of Human Coronavirus OC43 Genomes in Yeast via Transformation-Associated Recombination.通过转化相关重组在酵母中组装和诱变人冠状病毒OC43基因组
Bio Protoc. 2025 Aug 20;15(16):e5422. doi: 10.21769/BioProtoc.5422.
2
SARS-CoV-2 Receptor Binding Domain (RBD) Protein-Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体结合域（RBD）蛋白-蛋白缀合物在恒河猴中诱导出与刺突mRNA相似或更好的抗体反应。
Vaccines (Basel). 2025 Jun 17;13(6):648. doi: 10.3390/vaccines13060648.
3
A yeast-based reverse genetics system to generate HCoV-OC43 reporter viruses encoding an eighth subgenomic RNA.

本文引用的文献

1
C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire.C1q 使流感血凝素茎结合抗体能够阻止病毒附着，并拓宽了抗体逃逸的范围。
Sci Immunol. 2024 Mar 22;9(93):eadj9534. doi: 10.1126/sciimmunol.adj9534.
2
Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy.细胞表面核衣壳蛋白表达：一种β冠状病毒免疫调节策略。
Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2304087120. doi: 10.1073/pnas.2304087120. Epub 2023 Jul 3.
3
The coronavirus recombination pathway.
一种基于酵母的反向遗传学系统，用于产生编码第八个亚基因组RNA的人冠状病毒OC43报告病毒。
J Virol. 2025 Feb 25;99(2):e0167124. doi: 10.1128/jvi.01671-24. Epub 2025 Jan 30.
4
Reply to Masters: Recombinant coronavirus balances biosafety and benefit.致主编的回复：重组冠状病毒兼顾生物安全性与益处。
Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2416109121. doi: 10.1073/pnas.2416109121. Epub 2024 Oct 21.
5
Caution urged for work with newly constructed human coronavirus.在处理新构建的人类冠状病毒时需谨慎。
Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2415892121. doi: 10.1073/pnas.2415892121. Epub 2024 Oct 21.
6
Role of IgA1 protease-producing bacteria in SARS-CoV-2 infection and transmission: a hypothesis.产 IgA1 蛋白酶细菌在 SARS-CoV-2 感染和传播中的作用：一种假说。
mBio. 2024 Oct 16;15(10):e0083324. doi: 10.1128/mbio.00833-24. Epub 2024 Aug 29.
7
A balance between innovation and biosafety.创新与生物安全之间的平衡。
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2410451121. doi: 10.1073/pnas.2410451121. Epub 2024 Jul 8.
冠状病毒重组途径。
Cell Host Microbe. 2023 Jun 14;31(6):874-889. doi: 10.1016/j.chom.2023.05.003.
4
Viral persistence, reactivation, and mechanisms of long COVID.病毒持续存在、再激活与长新冠的机制。
Elife. 2023 May 4;12:e86015. doi: 10.7554/eLife.86015.
5
Real-world effectiveness of a single dose of mpox vaccine in males.一剂猴痘疫苗对男性的真实世界有效性。
Nat Med. 2023 Mar;29(3):748-752. doi: 10.1038/s41591-023-02229-3. Epub 2023 Jan 31.
6
Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.鼻内接种小儿副流感病毒载体 SARS-CoV-2 疫苗可保护猴子。
Cell. 2022 Dec 8;185(25):4811-4825.e17. doi: 10.1016/j.cell.2022.11.006. Epub 2022 Nov 10.
7
On the Origins of Omicron's Unique Spike Gene Insertion.关于奥密克戎独特刺突基因插入的起源
Vaccines (Basel). 2022 Sep 9;10(9):1509. doi: 10.3390/vaccines10091509.
8
A Mouse-Adapted Model of HCoV-OC43 and Its Usage to the Evaluation of Antiviral Drugs.人冠状病毒 OC43 的小鼠适应模型及其在抗病毒药物评价中的应用。
Front Microbiol. 2022 May 17;13:845269. doi: 10.3389/fmicb.2022.845269. eCollection 2022.
9
Recombination in Coronaviruses, with a Focus on SARS-CoV-2.冠状病毒中的重组，以 SARS-CoV-2 为例。
Viruses. 2022 Jun 7;14(6):1239. doi: 10.3390/v14061239.
10
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Codetection With Influenza A and Other Respiratory Viruses Among School-Aged Children and Their Household Members-12 March 2020 to 22 February 2022, Dane County, Wisconsin.严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 与甲型流感病毒及其他呼吸道病毒在学龄儿童及其家庭成员中的共同检出——威斯康星州戴恩县，2020 年 3 月 12 日至 2022 年 2 月 22 日。
Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S205-S215. doi: 10.1093/cid/ciac487.